Cutaneous manifestations of vemurafenib therapy for metastatic melanoma

Joshua L. Owen, Isha E. Lopez, Seemal R. Desai

Research output: Contribution to journalArticle

1 Citation (Scopus)

Abstract

Vemurafenib, a BRAF inhibitor, is FDA-approved for the treatment of metastatic melanoma in patients who harbor the BRAF V600E mutation. By inhibiting BRAF, vemurafenib prevents the mitogen-activated protein kinase (MAPK) pathway from driving melanoma growth. Here we present a patient with paradoxical activation of the MAPK pathway by vemurafenib, ultimately resulting in deleterious cutaneous manifestations. An emphasis on close follow-up is warranted for new or changing lesions for patients on this medication and other BRAF inhibitors.

Original languageEnglish (US)
Pages (from-to)509-510
Number of pages2
JournalJournal of drugs in dermatology : JDD
Volume14
Issue number5
StatePublished - May 1 2015

Fingerprint

Skin Manifestations
Melanoma
Mitogen-Activated Protein Kinases
Therapeutics
Mutation
Growth
PLX4032

ASJC Scopus subject areas

  • Dermatology

Cite this

Cutaneous manifestations of vemurafenib therapy for metastatic melanoma. / Owen, Joshua L.; Lopez, Isha E.; Desai, Seemal R.

In: Journal of drugs in dermatology : JDD, Vol. 14, No. 5, 01.05.2015, p. 509-510.

Research output: Contribution to journalArticle

@article{593436b36eb54a468acd1fc274708b3c,
title = "Cutaneous manifestations of vemurafenib therapy for metastatic melanoma",
abstract = "Vemurafenib, a BRAF inhibitor, is FDA-approved for the treatment of metastatic melanoma in patients who harbor the BRAF V600E mutation. By inhibiting BRAF, vemurafenib prevents the mitogen-activated protein kinase (MAPK) pathway from driving melanoma growth. Here we present a patient with paradoxical activation of the MAPK pathway by vemurafenib, ultimately resulting in deleterious cutaneous manifestations. An emphasis on close follow-up is warranted for new or changing lesions for patients on this medication and other BRAF inhibitors.",
author = "Owen, {Joshua L.} and Lopez, {Isha E.} and Desai, {Seemal R.}",
year = "2015",
month = "5",
day = "1",
language = "English (US)",
volume = "14",
pages = "509--510",
journal = "Journal of Drugs in Dermatology",
issn = "1545-9616",
publisher = "Journal of Drugs in Dermatology",
number = "5",

}

TY - JOUR

T1 - Cutaneous manifestations of vemurafenib therapy for metastatic melanoma

AU - Owen, Joshua L.

AU - Lopez, Isha E.

AU - Desai, Seemal R.

PY - 2015/5/1

Y1 - 2015/5/1

N2 - Vemurafenib, a BRAF inhibitor, is FDA-approved for the treatment of metastatic melanoma in patients who harbor the BRAF V600E mutation. By inhibiting BRAF, vemurafenib prevents the mitogen-activated protein kinase (MAPK) pathway from driving melanoma growth. Here we present a patient with paradoxical activation of the MAPK pathway by vemurafenib, ultimately resulting in deleterious cutaneous manifestations. An emphasis on close follow-up is warranted for new or changing lesions for patients on this medication and other BRAF inhibitors.

AB - Vemurafenib, a BRAF inhibitor, is FDA-approved for the treatment of metastatic melanoma in patients who harbor the BRAF V600E mutation. By inhibiting BRAF, vemurafenib prevents the mitogen-activated protein kinase (MAPK) pathway from driving melanoma growth. Here we present a patient with paradoxical activation of the MAPK pathway by vemurafenib, ultimately resulting in deleterious cutaneous manifestations. An emphasis on close follow-up is warranted for new or changing lesions for patients on this medication and other BRAF inhibitors.

UR - http://www.scopus.com/inward/record.url?scp=84986626911&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84986626911&partnerID=8YFLogxK

M3 - Article

C2 - 25942671

AN - SCOPUS:84986626911

VL - 14

SP - 509

EP - 510

JO - Journal of Drugs in Dermatology

JF - Journal of Drugs in Dermatology

SN - 1545-9616

IS - 5

ER -